Special Edition

Special Edition

AG-221 Clinical Results Promise “Revolutionary” Approach in AML

Early clinical findings with AG-221 – a first-in-class potent, selective oral inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) – reveal durable responses, including complete...

Promising Results for Elotuzumab Push Monoclonal Antibody Into Phase 3 Trial

Adding the new agent elotuzumab to traditional regimens of lenalidomide and low-dose dexamethasone has been found to produce high response rates in patients with...

Boosting Healthy Red Blood Cell Production to Target Anemia in MDS and Beta-Thalassemia

A new class of agents developed to enhance the production of healthy red blood cells (RBCs) provides a much-needed alternative to current treatment options...

New Treatment Option for Relapsed or Refractory Multiple Myeloma

Findings from a large clinical trial could pave the way for a new standard therapeutic approach to patients with refractory or relapsed and refractory...

New Drug Class Could Fill Unmet Need in Treatment of Multiple Myeloma

A new class of drugs designed to attack malignant plasma cells could offer patients with multiple myeloma new treatment options, according to early clinical...

Brentuximab Vedotin Delivers Clinical Results in Both Pre- and Post-Transplant Hodgkin Lymphoma

Brentuximab vedotin, an antibody-drug conjugate that targets CD30-positive cells, was the focus of much attention at the 56th ASH Annual Meeting. Two studies highlighted...

Update on Idelalisib + Rituximab in Relapsed and Elderly CLL Patients

The combination of idelalisib with rituximab prolonged progression-free survival (PFS) for patients with relapsed chronic lymphocytic leukemia (CLL), according to an oral presentation at...

Addition of Third Drug to Multiple Myeloma Regimen Slows Progression of Disease

A new research study has found that adding carfilzomib to a treatment regimen of lenalidomide and dexamethasone significantly improved progression-free survival (PFS) in patients...

Ibrutinib + Rituximab Benefits Patients With Pre-Treated Lymphoma and Leukemia

The combination of ibrutinib and rituximab is a promising treatment option for patients with relapsed or refractory blood cancers, according to results of two...

PD-1 Checkpoint Inhibitors Harness the Immune System to Treat Lymphomas

A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed and refractory lymphomas, according to...
Advertisement

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title